Johnson & Johnson (JNJ)

JNJ on New York Consolidated

102.47USD
10 Feb 2016
Change (% chg)

$0.50 (+0.49%)
Prev Close
$101.97
Open
$102.05
Day's High
$102.60
Day's Low
$102.00
Volume
1,107,304
Avg. Vol
8,579,477
52-wk High
$105.49
52-wk Low
$81.79

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $282,145.31
Shares Outstanding(Mil.): 2,766.94
Dividend: 0.75
Yield (%): 2.94

Financials

  JNJ Industry Sector
P/E (TTM): 18.62 31.54 38.00
EPS (TTM): 5.48 -- --
ROI: -- 14.88 14.26
ROE: -- 15.46 15.05
Search Stocks

Pfizer, J&J, Merck evaluating technologies for Zika vaccine

Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects.

03 Feb 2016

Pfizer, J&J, Merck evaluating technologies for Zika vaccine

Feb 3 Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects.

03 Feb 2016

J&J reportedly settles first transvaginal mesh suits

Johnson & Johnson's Ethicon Inc unit has reportedly reached a $120 million deal to resolve as many as 3,000 lawsuits alleging that its transvaginal mesh products are defective, marking the first time the manufacturer has agreed to a group settlement in the litigation.

27 Jan 2016

Investor pressures J&J to consider split up: sources

Artisan Partners, a major shareholder in Johnson & Johnson, has urged several activists to pressure the consumer products giant to consider major changes that include a potential split, according to sources and documents. Artisan has asked Johnson & Johnson’s management to consider separating its three divisions – consumer products, pharmaceuticals and medical devices – into standalone companies in hopes of unlocking up to $90 billion in enterprise value, said sources fam

27 Jan 2016

J&J profit beats forecasts, helped by lower taxes, cost cuts

Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, and gave a 2016 profit outlook slightly above Wall Street's.

26 Jan 2016

UPDATE 3-J&J profit beats forecasts, helped by lower taxes, cost cuts

Jan 26 Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, and gave a 2016 profit outlook slightly above Wall Street's.

26 Jan 2016

BRIEF-Imperial Innovations joins consortium to launch 40 mln stg therapeutics fund

* Innovations joins consortium of three world-leading UK universities and three global pharmaceutical companies to launch 40 million pounds ($57.22 million) therapeutics fund

25 Jan 2016

J&J to cut 3,000 jobs in struggling device division

Johnson & Johnson said on Tuesday it would cut about 3,000 jobs within its medical devices unit over the next two years, or about 4 to 6 percent of the struggling division's global workforce, to generate annual cost savings of up to $1 billion and focus on more innovative products.

19 Jan 2016

U.S. top court won't hear J&J appeal of $140 million judgment

The U.S. Supreme Court said on Tuesday it will not hear Johnson & Johnson's appeal of a $140 million judgment in a lawsuit alleging it failed to warn that Children's Motrin pain and fever medication could cause a devastating skin condition.

19 Jan 2016

U.S. top court won't hear J&J appeal of $140 million judgment

NEW YORK The U.S. Supreme Court said on Tuesday it will not hear Johnson & Johnson’s appeal of a $140 million judgment in a lawsuit alleging it failed to warn that Children’s Motrin pain and fever medication could cause a devastating skin condition.

19 Jan 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Acquisdata
$15.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks